Biological Monitoring of HER-2 Positive Patients Using Serum HER-2 and Circulating Tumor Cells
Annual rept. 1 Sep 2001-31 Aug 2002
DANA-FARBER CANCER INST BOSTON MA
Pagination or Media Count:
Evaluate the feasibility of detecting CTCs by CK19 mRNA in patients with HER-2 positive metastatic breast cancer and correlate this with serum HER-2 and clinical response to Herceptin therapy. PatientsMethods Blood samples were collected from 55 women with HER-2 positive lHC andor FlSH metastatic breast cancer and 30 healthy female volunteers Blood samples were collected at baseline, during With the first cycle of HN at weeks 2, 3 and 5, and at each restaging. Peripheral blood mononuclear cells were isolated and enriched for epithelial cells by immunomagnetic selection. Plasma was used to measure shed HER-2 extracellular domain using as commercially available kit. The presence of CKI 9- gene mRNA was determined by RTPCR using the LCx probe system Abbott. Thirty healthy donor blood samples were accessed as controls.
- Medicine and Medical Research
- Medical Facilities, Equipment and Supplies